Skip to content

Clinical Evaluation of a New Reduced Volume Bowel Preparation

A Pilot Monocentric, Open Phase II Study to Investigate the Efficacy and Safety of a New Oral Gut Cleansing Solution (Low Dose Bowel Prep) in 30 Patients Submitted to Colonoscopy

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00321230
Enrollment
30
Registered
2006-05-03
Start date
2001-01-31
Completion date
2001-05-31
Last updated
2008-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Keywords

Colon cleansing

Brief summary

Monocentric, cleansing evaluation pilot study in patients undergoing colonoscopy.

Detailed description

Open prospective pilot monocentric phase II clinical trial evaluating the therapeutic efficacy of a new Low Dose Bowel Prep formulation for gut cleansing prior to colonoscopy. Thirty patients admitted to the hospital (inpatients) planned to undergo a complete colonoscopy will have gut cleansing with the Low Dose Bowel Prep using a one-step intake mode.

Interventions

Sponsors

Norgine
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* male or female, inpatients 18 to 65 years old with indication for complete colonoscopy * the patient's written informed consent must be obtained prior to inclusion * willing and able to complete the entire procedure and to comply with study instructions

Exclusion criteria

* ileus or toxic megacolon * intestinal obstruction or perforation * known of G6PD insufficiency * history of any colonic surgery * ischaemic cardiovascular disease * untreated or uncontrolled arterial hypertension (max \>170mmHg, min \>100mmHg) * renal insufficiency (creating above 45µmol/l) * abnormal laboratory values (clinically significant) for sodium, potassium,chloride, creatinine and hematocrit * cirrhosis of liver (Child-Pugh grade B or C) * females who are pregnant, nursing or planning a pregnancy. Females of child bearing potential not using reliable methods of contraception. * concurrent participation in an investigational drug study or participation within 30 days of study entry * subject has a condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound the study results or may interfere significantly

Design outcomes

Primary

MeasureTime frame
Efficacy measured by a final scoring system i.e., the overall quality of colonoscopy prep that will be graded (from A to C) and assessed from the degree of cleansing in a 0 - 4 grade scale for each of the predefined colon areas.

Secondary

MeasureTime frame
Stool weight as recorded on the case report form for each stool as from start of gut cleansing (day -1) to the beginning of colonoscopy (day 0).
Amount of fluid removed from the colon during the colonoscopy.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026